This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function

This study has been completed.
Information provided by (Responsible Party):
Helsinn Therapeutics (U.S.), Inc Identifier:
First received: January 13, 2011
Last updated: April 12, 2017
Last verified: April 2017
Post-operative administration of ipamorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial small and/or large bowel resection.

Condition Intervention Phase
Gastrointestinal Dysmotility Drug: Saline Solution for Injection Drug: Ipamorelin Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase II Double-Blind Placebo-Controlled Dose Finding Study to Evaluate Safety/Efficacy of Ipamorelin Compared to Placebo for Recovery of Gastrointestinal Function in Patients Following Small or Large Bowel Resection w/Primary Anastomosis

Further study details as provided by Helsinn Therapeutics (U.S.), Inc:

Primary Outcome Measures:
  • Recovery of Gastrointestinal (GI) Function [ Time Frame: Up to 10 days ]
    To assess the efficacy of three repeated dose levels of ipamorelin vs. placebo

Secondary Outcome Measures:
  • Ancillary GI Functions [ Time Frame: Up to 10 days or until hospital discharge ]
    To investigate the effect of ipamorelin on ancillary efficacy measures of GI function and recovery

  • Number of Subjects with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 14 day outpatient follow-up visit ]
    To investigate the safety and tolerability of ipamorelin laboratory and clinical parameters, incidence of adverse events, until hospital discharge, 14-day outpatient follow-up visit, or until resolution of adverse events

Enrollment: 320
Actual Study Start Date: April 2011
Study Completion Date: May 2014
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 0.03 mg/kg BID
Ipamorelin 0.03 mg/kg, BID (2 investigational drug infusions and 1 placebo infusion)
Drug: Ipamorelin
Intravenous (IV)
Experimental: 0.06 mg/kg BID
Ipamorelin 0.06 mg/kg, BID (2 investigational drug infusions and 1 placebo infusion)
Drug: Ipamorelin
Intravenous (IV)
Experimental: 0.06 mg/kg TID
Ipamorelin 0.06 mg/kg, TID (3 investigational drug infusions)
Drug: Ipamorelin
Intravenous (IV)
Placebo Comparator: Placebo
Matching placebo, TID (3 placebo infusions)
Drug: Saline Solution for Injection
Intravenous (IV)


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Able to freely give written informed consent to participate in the study and have signed the Informed Consent Form
  • Males or females, 18 to 85 years of age inclusive at the time of study screening
  • American Society of Anesthesiologists (ASA) Class I-III
  • Have undergone a scheduled small and/or large open partial bowel resection based on a documented incision size greater than or equal to (≥) 10 cm with primary anastomosis
  • Females must not be pregnant as confirmed by a serum pregnancy test at screening and by a urine pregnancy test on the day of surgery
  • Body weight must be between 40-150 kilograms (kg)

Exclusion Criteria:

  • Any procedure which requires a diverting stoma
  • Primary anastomosis not performed at the time of surgery
  • Epidural or intrathecal anesthesia
  • Significant liver disease (ALT and/or total bilirubin > 2-fold upper limits of normal) or kidney disease (serum creatinine > 2.5 mg/dL) at screening
  • History of irritable bowel syndrome
  • Patients with a history of Crohn's disease or ulcerative colitis (UC) who have had multiple GI-related surgeries (Note: surgery naïve Crohn's or UC patients may be included)
  • History of colonic volvulus
  • History of gastroesophageal surgery, gastrectomy, gastric bypass, total colectomy, short bowel syndrome, or multiple complex abdominal surgeries performed by an open procedure (uncomplicated cesarean section and appendectomy would not be considered complex)
  • Patients who have received prior abdominal radiation and/or pelvic radiation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01280344

  Show 45 Study Locations
Sponsors and Collaborators
Helsinn Therapeutics (U.S.), Inc
  More Information

Responsible Party: Helsinn Therapeutics (U.S.), Inc Identifier: NCT01280344     History of Changes
Other Study ID Numbers: HT-IPAM-202
Study First Received: January 13, 2011
Last Updated: April 12, 2017 processed this record on August 18, 2017